Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04362865 · ClinicalTrials.gov registry record
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 679
- Enrollment target
NCT04362865: Completed study, sponsored by National Cancer Institute (NCI).
NCT04362865 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 679 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04362865 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 679 participants
- Enrollment target
Study Summary
Background: People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital. Researchers think the risk may be related to how a person s B and T cells respond to the virus. B and T cells are the major components of a person s immune response. B and T cells responding to the virus with a favorable pattern may lead to recovery, and this favorable pattern may be helpful to establish. If people in a vaccine trial get this same favorable pattern when responding to a vaccine, this may be a useful early signal that the vaccine will be successful. Objective: To examine how immune cells respond to COVID-19 infection. Eligibility: Adults ages 18 and older who have a confirmed or suspected COVID-19 infection or had COVID-19 in the past. Also, healthy donors with no suspected COVID-19 infection Design: Participants will be screened with medical record review. Participants will be tested with a research assay to determine who was infected with COVID-19 and who was not. This test will be used to understand research results, not to advise patients. Participants with active infection must be isolated, usually in a hospital. Other participants may give blood samples at NIH or at their local doctor s office or lab. Participants may give blood samples up to three times a week for a total of ten times, and may also give blood samples after starting a vaccine trial. Participants will be contacted by phone or email every 2 months for up to 2 years.
Primary Outcome
characterize immune response in patients with active or prior COVID-19 infection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 679 participants |
| Start Date | 2020-04-27 |
| Est. Completion | 2025-02-10 |
What the finished NCT04362865 record still lists
NCT04362865 is an observational study that tracks outcomes without assigning an intervention. The registered 679 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04362865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04362865 about?
NCT04362865 is a clinical study titled "Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection". Background: People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital. Researchers think the risk may be related to how a person s B and T cells respond to the virus. B and T ce...
What is the current status of trial NCT04362865?
This trial is currently completed. The enrollment target is 679 participants. The study started on 2020-04-27. Estimated completion is 2025-02-10.
Who is sponsoring clinical trial NCT04362865?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI